iSOFT moves into life sciences market
16 Dec 2010
iSOFT Group Limited (ASX:ISF) has moved into the life sciences
market with software that extracts and de-identifies clinical data from
electronic medical records for clinical research and other secondary
The move follows a co-marketing agreement with US-based
CliniWorks for its AccelFind solutions. CliniWorks has developed the
technology behind AccelFind, and provides it as a service, to
extract medical knowledge from any type of data, including free text
notes, discharge summaries or the structured data contained in
electronic medical records and laboratory systems.
With the new agreement, iSOFT will market AccelFind as part of
its Life Science Solution “powered by CliniWorks” to hospitals and
life science companies worldwide.
Meanwhile Cytolon, a Berlin-based enabling technology company for
personalized medicine, will integrate the new tool with its platform
CordMatch. CordMatch is a unique, web-based platform that integrates
product search and matching-to-patient, logistics, billing and
follow-up for the matching of stem cell products.
The Life Sciences Solution, will also be integrated with
CordMatch and provide a powerful tool allowing the secondary use of
electronic health records, so offering a whole new world of
possibilities for clinical development, adding value for
pharmaceutical companies and permitting ultimately the improvement
of therapy quality and fostering personalized medicine. Benefits
generated from these projects will be shared between the companies.
Cytolon supports and participates in clinical research studies
for the development of future applications of stem cell products
derived from umbilical cord blood for a variety of diseases.
The iSOFT Life Sciences solution integrates with all standard
hospital databases to extract clinical information and so promotes
knowledge collaboration for highly efficient clinical research,
outcomes tracking and management.
iSOFT’s Director for Life Sciences, Dr Joerg Kraenzlein, said:
“This is a tremendous opportunity to accelerate clinical research in
a so far unprecedented way, and tap into new areas of treatment
options and value propositions that have the potential to change the
way we perform medicine and use healthcare IT today.”
iSOFT’s Chief Medical Officer, Dr Michael Dahlweid, added: “Life
Sciences is a new strategic asset of iSOFT’s solution portfolio with
a huge growth potential and perfectly fits our Smart Solution
approach, which provides instant value to existing and new